Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GenSci134 in pediatric idiopathic short stature (Ib/II, China)
CTR20260171Phase 2Active
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GenSci134 in Idiopathic Short Stature (ISS) (2 arms), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Treatment-emergent adverse events (TEAEs), vital signs, physical examination, laboratory tests, 12-lead ECG, injection site reactions (Phase Ib) and Annualized height velocity (AHV) after treatment (Phase II). Started Jan 2026; status: active.
02
Drugs
GenSci134
03
Conditions
Idiopathic Short Stature (ISS)
Beyond the preview
Go deeper on CTR20260171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260171.